A MARKOV MODEL EVALUATING THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO VEDOLIZUMAB FOR PATIENT'S WITH CROHN'S DISEASE AS THIRD-LINE THERAPY

被引：1
|
作者：
Schneider, Yecheskel
Saumoy, Monica
Cohen-Mekelburg, Shirley A.
Gold, Stephanie
Scherl, Ellen
Steinlauf, Adam F.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)32115-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1899
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 50 条
  • [41] The cost-effectiveness of biological therapies for crohn's disease: markov cohort analyses incorporating uk patient-level cost data
    Bodger, K.
    Kikuchi, T.
    Hughes, D. A.
    [J]. GUT, 2008, 57 : A48 - A48
  • [42] An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients
    Kawalec, Pawel
    Mocko, Pawel
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (02) : 101 - 111
  • [43] Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
    Biemans, Vince B. C.
    van der Woude, C. Janneke
    Dijkstra, Gerard
    van der Meulen-de Jong, Andrea E.
    Lowenberg, Mark
    de Boer, Nanne K.
    Oldenburg, Bas
    Srivastava, Nidhi
    Jansen, Jeroen M.
    Bodelier, Alexander G. L.
    West, Rachel L.
    de Vries, Annemarie C.
    Haans, Jeoffrey J. L.
    de Jong, Dirk
    Hoentjen, Frank
    Pierik, Marieke J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 123 - 134
  • [44] Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn's Disease
    Kappelman, Michael
    Lewis, James D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica L.
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Long, Millie
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S676 - S676
  • [45] MULTI-CENTRE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB AS INDUCTION THERAPY IN ANTI-TNF REFRACTORY CROHN'S DISEASE
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daneil
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Sabine, Joseph
    Chapman, Adam
    Reilly, Ian
    Flanagan, Paul
    Bodger, Keith
    Subramanian, Sreedhar
    [J]. GUT, 2019, 68 : A100 - A100
  • [46] Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn?s disease
    Melotti, Laura
    Dussias, Nikolas Konstantine
    Salice, Marco
    Calabrese, Carlo
    Baldoni, Monia
    Scaioli, Eleonora
    Belluzzi, Andrea
    Mazzotta, Elena
    Gionchetti, Paolo
    Rizzello, Fernando
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 230 - 234
  • [47] Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn's disease
    Dussias, N.
    Rizzello, F.
    Calabrese, C.
    Passino, A. Sanna
    Melotti, L.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S528 - S528
  • [48] Pyostomatitis Vegetans in a Patient With Crohn's Disease: A Case Report on the Effectiveness of Ustekinumab
    Hashash, Jana
    Abbas, Ossama
    Doumeth, Sarah Abi
    Hosni, Mohamad
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S1 - S1
  • [49] The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease
    Zhao, Mirabella
    Burisch, Johan
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 (05): : 573 - 574
  • [50] COST-EFFECTIVENESS OF ADALIMUMAB FOR TREATMENT OF CROHN'S DISEASE IN GERMANY
    Yang, M.
    Yang, M.
    Skup, M.
    Zhou, Z. Y.
    Hengst, N.
    Wolff, M.
    Mulani, P. M.
    Chao, J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A329 - A329
12345